Employees in special suits test procedures for manufacturing the messenger RNA (mRNA) COVID-19 vaccine from Pfizer-BioNTech, in Marburg, Germany.

Drugmakers big and small are storming into messenger RNA research.
The technology behind the first COVID-19 vaccines could help fight other diseases, including cancer.
Early leaders in the mRNA space include Moderna, BioNTech, Pfizer, Sanofi, and GlaxoSmitKline.
This article is part of a series called “Future of Healthcare,” which explores how technology is driving innovation in the development of healthcare.

While the COVID-19 pandemic will be remembered as a scourge on humanity, there are silver linings.

Perhaps the biggest success story has been coronavirus vaccines, which were developed in record time and have undoubtedly saved millions of lives. Looking beyond the pandemic, the underlying technology behind the leading COVID-19 shots could also be useful for many other diseases, potentially leading to dozens of new treatments and vaccines over time.

The first vaccines, developed by Pfizer-BioNTech and Moderna, are based on a new technology platform called messenger RNA, or mRNA. While drug companies have been working on mRNA-based medicines for years, the COVID-19 vaccines are the first mRNA vaccines to be authorized and widely used.

Now, scientists are eager to usher in a new era of medicine, applying the learnings from COVID-19 to a range of illnesses, including cancer, HIV, and rare diseases.

Only a few years ago, mRNA was seen as a promising but unproven idea in drug development. Now, the world’s largest drugmakers – like Pfizer, GlaxoSmithKline, and Sanofi – are building their mRNA capabilities as the pandemic has vaulted relatively smaller biotechs like Moderna and BioNTech to record valuations.

  Africa is poised to be a significant player in the new space age - especially when it comes to governance. Here's why.

mRNA taps into genetic insights over the past decades

Many vaccines aim to deliver a crucial protein to cells to teach them to fight off a certain pathogen. The mRNA approach uses genetics to go a step back in that process.

Our cells convert DNA to RNA molecules. RNA tells cells how to produce proteins. mRNA vaccines deliver those genetic instructions to build a certain protein, rather than the protein itself.

Drug engineers can design mRNA therapies to control which protein to make and how much. That mRNA sequence is then placed in a microscopic blob of fat, called a lipid nanoparticle, which carries the genetic payload into our cells.

Because mRNA therapies can theoretically be designed in the lab, mRNA holds the promise of addressing a wide range of diseases. Moderna CEO Stephane Bancel often calls it “plug-and-play” technology, where scientists can design additional mRNA sequences with a higher-than-usual chance they’ll work.

The mRNA pipeline extends beyond COVID-19

The mRNA technology won’t be limited to vaccines.

Moderna is already testing in human studies potential vaccines against the flu, cytomegalovirus, respiratory syncytial virus, and Zika. Vaccines against the mononucleosis-causing Epstein-Barr virus, the Nipah virus, and HIV are still in the earliest stages of research. The Massachusetts biotech is also developing mRNA treatments for the Chikungunya virus and is exploring research into auto-immune disorders …read more

Source:: Business Insider


(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *